| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Kary Eldred is Director at GALT. From September 2018 to February 2026, the filings on record show 13 open-market purchases and 0 sales. Kary Eldred's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $220K at current prices.
Our model assigns Kary Eldred a strong insider score of 81/100, based on 9 past trades. Over a 12-month horizon, 85.7% of those trades were profitable, with an average 12-month return of +47.9%.
Net of sales, the GALT filings show accumulation of 26,500 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 25, 2023 | GALT Galectin Therapeutics Inc | Director | Buy | 1,300 | $1.11 | $1,443.00 | +2.9% | +59.1% | +62.7% | |
| May 31, 2019 | GALT Galectin Therapeutics Inc | Director | Buy | 3,033 | $4.28 | $12,981.24 | +7.3% | - | - | |
| Sep 25, 2018 | GALT Galectin Therapeutics Inc | Director | Buy | 2,000 | $6.10 | $12,199.80 | +5.1% | - | - |